☰

Chen Ling, Ph.D - Publications

Affiliations: 
Pediatrics University of Florida, Gainesville, Gainesville, FL, United States 
Area:
AAV, Gene Therapy
Tree Info Similar researchers PubMed Report error

55 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Xie YL, Wang JY, He Y, Yu XM, Zheng QY, Ling C, Feng XL, Zhu LQ. The use of melittin to enhance transgene expression mediated by recombinant adeno-associated virus serotype 2 vectors both in vitro and in vivo. Journal of Integrative Medicine. PMID 36333178 DOI: 10.1016/j.joim.2022.10.003  0.33
2020 Brown HC, Doering CB, Herzog R, Ling C, Markusic DM, Spencer HT, Srivastava A, Srivastava A. Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B. Human Gene Therapy. PMID 32657150 DOI: 10.1089/Hum.2020.099  0.418
2020 Yang H, Qing K, Keeler GD, Yin L, Mietzsch M, Ling C, Hoffman BE, Agbandje-McKenna M, Tan M, Wang W, Srivastava A. Enhanced Transduction of Human Hematopoietic Stem Cells by AAV6 Vectors: Implications in Gene Therapy and Genome Editing. Molecular Therapy. Nucleic Acids. 20: 451-458. PMID 32276210 DOI: 10.1016/J.Omtn.2020.03.009  0.446
2020 Ran G, Chen X, Xie Y, Zheng Q, Xie J, Yu C, Pittman N, Qi S, Yu FX, Agbandje-McKenna M, Srivastava A, Ling C. Site-Directed Mutagenesis Improves the Transduction Efficiency of Capsid Library-Derived Recombinant AAV Vectors. Molecular Therapy. Methods & Clinical Development. 17: 545-555. PMID 32258217 DOI: 10.1016/J.Omtm.2020.03.007  0.434
2020 Yin L, Keeler GD, Zhang Y, Hoffman BE, Ling C, Qing K, Srivastava A. AAV3-miRNA vectors for growth suppression of human hepatocellular carcinoma cells in vitro and human liver tumors in a murine xenograft model in vivo. Gene Therapy. PMID 32152434 DOI: 10.1038/S41434-020-0140-1  0.342
2019 Pan D, Büning H, Ling C. Rational Design of Gene Therapy Vectors. Molecular Therapy. Methods & Clinical Development. 12: 246-247. PMID 30815510 DOI: 10.1016/J.Omtm.2019.01.009  0.325
2018 Feng Y, Yin Z, Zhang D, Srivastava A, Ling C. Chinese medicine protein and peptide in gene and cell therapy. Current Protein & Peptide Science. PMID 29895243 DOI: 10.2174/1389203719666180612082432  0.343
2016 Ling C, Bhukhai K, Yin Z, Tan M, Yoder MC, Leboulch P, Payen E, Srivastava A. High-Efficiency Transduction of Primary Human Hematopoietic Stem/Progenitor Cells by AAV6 Vectors: Strategies for Overcoming Donor-Variation and Implications in Genome Editing. Scientific Reports. 6: 35495. PMID 27759036 DOI: 10.1182/Blood.V128.22.5889.5889  0.427
2016 Ling C, Li B, Ma W, Srivastava A. Development of Optimized AAV Serotype Vectors for High-Efficiency Transduction at Further Reduced Doses. Human Gene Therapy Methods. PMID 27431826 DOI: 10.1089/Hgtb.2016.054  0.419
2016 Ling C, Yin Z, Li J, Zhang D, Aslanidi G, Srivastava A. Strategies to generate high-titer, high-potency recombinant AAV3 serotype vectors. Molecular Therapy. Methods & Clinical Development. 3: 16029. PMID 27200382 DOI: 10.1038/Mtm.2016.29  0.474
2016 Lu Y, Marsic D, Ling C, Guijario MV, Levings PP, Palmer GD, Dacanay A, Watson-Levings RS, Hyddmark V, White ME, Zolotukhin S, Ghivizzani SC. 723. AAV Mediated Cancer Targeting: Systemic Trafficking to Tumor Is More Important Than Vector Tumor Cell Interaction Molecular Therapy. 24. DOI: 10.1016/S1525-0016(16)33531-6  0.321
2016 Ling C, Yin Z, Li J, Zhang D, Aslanidi G, Srivastava A. 548. Recombinant AAV3 Serotype Vectors Generated by Using AAV3 ITRs and AAV3 Rep Proteins Efficiently Transduce Human Liver Cancer Cell Lines In Vitro and Human Liver Tumors in a Murine Xenograft Model In Vivo Molecular Therapy. 24: S219-S220. DOI: 10.1016/S1525-0016(16)33356-1  0.462
2016 Zhang D, Ling C, Aslanidi G. 196. Nordihydroguaiaretic Acid (NDGA) Improves Function of Antigen-Specific T-Cells Stimulated by Capsid-Optimized AAV6 Vectors Molecular Therapy. 24. DOI: 10.1016/S1525-0016(16)33005-2  0.376
2016 Zhang D, Li J, Feng Y, Snowden A, Aslanidi G, Muzyczka N, Srivastava A, Ling C, Ling C. 95. Incorporation of AAV Serotype 2 Viral Protein 2 into Other AAV Serotype Capsids Molecular Therapy. 24: S41-S42. DOI: 10.1016/S1525-0016(16)32904-5  0.438
2016 Ling C, Li B, Ma W, Aslanidi G, Srivastava A. 91. Development of Optimized [“Opt”] AAV Vectors by Combining Capsid-Modified NextGen and Genome-Modified GenX AAV Vectors for High-Efficiency Transduction at Further Reduced Doses Molecular Therapy. 24: S39-S40. DOI: 10.1016/S1525-0016(16)32900-8  0.442
2016 Ling C, Li J, Zhang D, Aslanidi G, Ling C, Srivastava A. 11. The Role of Glucocorticoid Receptor Signaling in Adeno-Associated Virus 2 Infection Molecular Therapy. 24: S6. DOI: 10.1016/S1525-0016(16)32820-9  0.424
2016 Yin Z, Bukhai K, Aslanidi G, Ling C, Tan M, Yoder M, Leboulch P, Payen E, Srivastava A. 10. High-Efficiency Transduction of Primary Human CD34+ Hematopoietic Stem/Progenitor Cells by AAV6 Serotype Vectors: Strategies for Overcoming Donor Variation and Implications in Genome Editing Molecular Therapy. 24: S5-S6. DOI: 10.1016/S1525-0016(16)32819-2  0.431
2015 Srivastava A, Li B, Ma W, Ling C, Van Vliet K, Huang LY, Agbandje-McKenna M, Aslanidi GV. Site-directed mutagenesis of surface-exposed lysine residues leads to improved transduction by AAV2, but not AAV8 vectors in murine hepatocytes in vivo. Human Gene Therapy Methods. PMID 26421998 DOI: 10.1089/Hgtb.2015.115  0.305
2015 Li S, Ling C, Zhong L, Li M, Su Q, He R, Tang Q, Greiner DL, Shultz LD, Brehm MA, Flotte TR, Mueller C, Srivastava A, Gao G. Efficient and targeted transduction of nonhuman primate liver with systemically delivered optimized AAV3B vectors. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 26403887 DOI: 10.1038/Mt.2015.174  0.417
2015 Ling C, Wang Y, Feng YL, Zhang YN, Li J, Hu XR, Wang LN, Zhong MF, Zhai XF, Zolotukhin I, Srivastava A, Ling CQ. Prevalence of neutralizing antibodies against liver-tropic adeno-associated virus serotype vectors in 100 healthy Chinese and its potential relation to body constitutions. Journal of Integrative Medicine. 13: 341-6. PMID 26343106 DOI: 10.1016/S2095-4964(15)60200-X  0.355
2015 Wang L, Yin Z, Wang Y, Lu Y, Zhang D, Srivastava A, Ling C, Aslanidi GV, Ling C. Productive life cycle of adeno-associated virus serotype 2 in the complete absence of a conventional polyadenylation signal. The Journal of General Virology. 96: 2780-7. PMID 26297494 DOI: 10.1099/Jgv.0.000229  0.322
2015 Sayroo R, Nolasco D, Yin Z, Colon-Cortes Y, Pandya M, Ling C, Aslanidi G. Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Therapy. PMID 26270885 DOI: 10.1038/Gt.2015.89  0.456
2015 Pandya M, Britt K, Hoffman B, Ling C, Aslanidi GV. Reprogramming Immune Response With Capsid-Optimized AAV6 Vectors for Immunotherapy of Cancer. Journal of Immunotherapy (Hagerstown, Md. : 1997). 38: 292-8. PMID 26261893 DOI: 10.1097/Cji.0000000000000093  0.424
2015 Ling C, Wang Y, Lu Y, Wang L, Jayandharan GR, Aslanidi GV, Li B, Cheng B, Ma W, Lentz T, Ling C, Xiao X, Samulski RJ, Muzyczka N, Srivastava A. Enhanced transgene expression from recombinant single-stranded D-sequence-substituted adeno-associated virus vectors in human cell lines in vitro and in murine hepatocytes in vivo. Journal of Virology. 89: 952-61. PMID 25355884 DOI: 10.1128/Jvi.02581-14  0.373
2015 Zhang Y, Wang Y, Wang L, Aslanidi G, Srivastava A, Ling C, Ling C. Abstract 5339: Cytotoxic genes from traditional Chinese medicine inhibit tumor growth both in vitro and in vivo Cancer Research. 75: 5339-5339. DOI: 10.1158/1538-7445.Am2015-5339  0.41
2015 Sayroo R, Yin Z, Nolasco D, Pandya M, Ling C, Aslanidi G. Abstract 3534: Development of the novel AAV-based vectors with selective tropism to human cancer cells Cancer Research. 75: 3534-3534. DOI: 10.1158/1538-7445.Am2015-3534  0.351
2015 Wang L, Ling C, Wang M, Yin Z, Ling C, Li M. 639. Combination Therapy of Bufalin and rAd-p53 for the Treatment of Hepatocellular Carcinoma In Vivo Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)34248-4  0.334
2015 Yin Z, Aslanidi GV, Ling C, Zhang Y, Ling C, Tan M, Yoder MC, Srivastava A. 550. Primary Human CD34+ Hematopoietic Stem/Progenitor Cell (HSPC) Transduction By AAV6 Serotype Vectors: Strategies for Overcoming the Donor-Variation Molecular Therapy. 23: S220-S221. DOI: 10.1016/S1525-0016(16)34159-4  0.448
2015 Colon-Cortes Y, Sharma P, Ling C, Abu-Hasan M, Srivastava A, Aslanidi G. 318. Development of Optimized AAV Serotype Vectors for the Potential Gene Therapy of Cystic Fibrosis Molecular Therapy. 23: S128. DOI: 10.1016/S1525-0016(16)33927-2  0.443
2015 Nolasco D, Van Vliet K, Markusic D, Ling C, Huang L, Agbandje-McKenna M, Srivastava A, Aslanidi G. 315. Optimization of the Capsid of Recombinant Adeno-Associated Virus 6 (AAV6) Vectors for Liver-, and Muscle-Directed Gene Therapy Molecular Therapy. 23: S127. DOI: 10.1016/S1525-0016(16)33924-7  0.392
2015 Sayroo R, Yin Z, Nalasco D, Pandya M, Ling C, Ling C, Aslanidi G. 313. Development of the AAV6-Based Vectors With Selective Tropism and High Transduction Efficiency of Human Cancer Cells Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)33922-3  0.471
2015 Ling C, Lu Y, Zhang Y, Li B, Ma W, Aslanidi GV, Ling C, Srivastava A. 310. Development of Generation X Recombinant AAV Vectors for Human Gene Therapy Molecular Therapy. 23: S125. DOI: 10.1016/S1525-0016(16)33919-3  0.411
2015 Pandya M, Britt K, Ling C, Hoffman B, Aslanidi G. 221. The Utilization of Capsid-Optimized Adeno-Associated Virus (AAV) Vectors for Cancer Immunotherapy Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)33826-6  0.397
2015 Ling C, Yin Z, Diaz A, Zhang Y, Zhang D, Aslanidi GV, Ling C, Srivastava A. 101. Generation of Improved Recombinant AAV3 Serotype Vectors Using AAV3 ITRS and AAV3 REP Proteins Molecular Therapy. 23: S42. DOI: 10.1016/S1525-0016(16)33706-6  0.475
2015 Yin Z, Wang Y, Zhang Y, Ashby R, Fajardo-Ashby M, Aslanidi G, Ling C, Srivastava A, Ling C. 100. Multifunctional Drug Enhances rAAV-Mediated Transgene Expression Through Different Mechanisms in Different Cell Types Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)33705-4  0.417
2015 Yin Z, Aslanidi GV, Ling C, Zhang Y, Ling C, Tan M, Yoder MC, Srivastava A. 99. A Novel Mechanism of Transduction of Human Cells By Recombinant AAV Vectors Molecular Therapy. 23: S41-S42. DOI: 10.1016/S1525-0016(16)33704-2  0.376
2014 Zhang YH, Wang Y, Yusufali AH, Ashby F, Zhang D, Yin ZF, Aslanidi GV, Srivastava A, Ling CQ, Ling C. Cytotoxic genes from traditional Chinese medicine inhibit tumor growth both in vitro and in vivo. Journal of Integrative Medicine. 12: 483-94. PMID 25412666 DOI: 10.1016/S2095-4964(14)60057-1  0.381
2014 Ling C, Wang Y, Zhang Y, Ejjigani A, Yin Z, Lu Y, Wang L, Wang M, Li J, Hu Z, Aslanidi GV, Zhong L, Gao G, Srivastava A, Ling C. Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Human Gene Therapy. 25: 1023-34. PMID 25296041 DOI: 10.1089/Hum.2014.099  0.437
2014 Ling CQ, Wang LN, Wang Y, Zhang YH, Yin ZF, Wang M, Ling C. The roles of traditional Chinese medicine in gene therapy. Journal of Integrative Medicine. 12: 67-75. PMID 24666672 DOI: 10.1016/S2095-4964(14)60019-4  0.309
2014 Wang LN, Wang Y, Lu Y, Yin ZF, Zhang YH, Aslanidi GV, Srivastava A, Ling CQ, Ling C. Pristimerin enhances recombinant adeno-associated virus vector-mediated transgene expression in human cell lines in vitro and murine hepatocytes in vivo. Journal of Integrative Medicine. 12: 20-34. PMID 24461592 DOI: 10.1016/S2095-4964(14)60003-0  0.459
2014 Ten E, Ling C, Wang Y, Srivastava A, Dempere LA, Vermerris W. Lignin nanotubes as vehicles for gene delivery into human cells. Biomacromolecules. 15: 327-38. PMID 24308459 DOI: 10.1021/Bm401555P  0.329
2014 Pandya J, Ortiz L, Ling C, Rivers AE, Aslanidi G. Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy. Immunology and Cell Biology. 92: 116-23. PMID 24217810 DOI: 10.1038/Icb.2013.74  0.344
2013 Tartaglia LJ, Bennett A, Plattner AS, Muzyczka N, Ling C, Srivastava A, Agbandje-McKenna M. Molecular cloning, overexpression, and an efficient one-step purification of α5β1 integrin. Protein Expression and Purification. 92: 21-8. PMID 23993979 DOI: 10.1016/J.Pep.2013.08.013  0.315
2013 Song L, Kauss MA, Kopin E, Chandra M, Ul-Hasan T, Miller E, Jayandharan GR, Rivers AE, Aslanidi GV, Ling C, Li B, Ma W, Li X, Andino LM, Zhong L, et al. Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors in primary human hematopoietic stem cells in vitro and in a xenograft mouse model in vivo. Cytotherapy. 15: 986-98. PMID 23830234 DOI: 10.1016/J.Jcyt.2013.04.003  0.44
2013 Aslanidi GV, Rivers AE, Ortiz L, Song L, Ling C, Govindasamy L, Van Vliet K, Tan M, Agbandje-McKenna M, Srivastava A. Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? Plos One. 8: e59142. PMID 23527116 DOI: 10.1371/Journal.Pone.0059142  0.419
2013 Song L, Li X, Jayandharan GR, Wang Y, Aslanidi GV, Ling C, Zhong L, Gao G, Yoder MC, Ling C, Tan M, Srivastava A. High-efficiency transduction of primary human hematopoietic stem cells and erythroid lineage-restricted expression by optimized AAV6 serotype vectors in vitro and in a murine xenograft model in vivo. Plos One. 8: e58757. PMID 23516552 DOI: 10.1371/Journal.Pone.0058757  0.427
2012 Wang Y, Ling C, Song L, Wang L, Aslanidi GV, Tan M, Ling C, Srivastava A. Limitations of encapsidation of recombinant self-complementary adeno-associated viral genomes in different serotype capsids and their quantitation. Human Gene Therapy Methods. 23: 225-33. PMID 22966785 DOI: 10.1089/Hgtb.2012.090  0.31
2012 Aslanidi GV, Rivers AE, Ortiz L, Govindasamy L, Ling C, Jayandharan GR, Zolotukhin S, Agbandje-McKenna M, Srivastava A. High-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors. Vaccine. 30: 3908-17. PMID 22497875 DOI: 10.1016/J.Vaccine.2012.03.079  0.43
2012 Cheng B, Ling C, Dai Y, Lu Y, Glushakova LG, Gee SW, McGoogan KE, Aslanidi GV, Park M, Stacpoole PW, Siemann D, Liu C, Srivastava A, Ling C. Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells. Gene Therapy. 19: 375-84. PMID 21776025 DOI: 10.1038/Gt.2011.105  0.472
2011 Ling C, Lu Y, Cheng B, McGoogan KE, Gee SW, Ma W, Li B, Aslanidi GV, Srivastava A. High-efficiency transduction of liver cancer cells by recombinant adeno-associated virus serotype 3 vectors. Journal of Visualized Experiments : Jove. PMID 21445055 DOI: 10.3791/2538  0.448
2011 Ma W, Li B, Ling C, Jayandharan GR, Srivastava A, Byrne BJ. A simple method to increase the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo. Human Gene Therapy. 22: 633-40. PMID 21219084 DOI: 10.1089/Hum.2010.243  0.432
2010 Markusic DM, Herzog RW, Aslanidi GV, Hoffman BE, Li B, Li M, Jayandharan GR, Ling C, Zolotukhin I, Ma W, Zolotukhin S, Srivastava A, Zhong L. High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 2048-56. PMID 20736929 DOI: 10.1038/Mt.2010.172  0.439
2010 Ling C, Lu Y, Kalsi JK, Jayandharan GR, Li B, Ma W, Cheng B, Gee SW, McGoogan KE, Govindasamy L, Zhong L, Agbandje-McKenna M, Srivastava A. Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3. Human Gene Therapy. 21: 1741-7. PMID 20545554 DOI: 10.1089/Hum.2010.075  0.405
2010 Li M, Jayandharan GR, Li B, Ling C, Ma W, Srivastava A, Zhong L. High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy. Human Gene Therapy. 21: 1527-43. PMID 20507237 DOI: 10.1089/Hum.2010.005  0.438
2009 Verma D, Ling C, Johannsen E, Nagaraja T, Swaminathan S. Negative autoregulation of Epstein-Barr virus (EBV) replicative gene expression by EBV SM protein. Journal of Virology. 83: 8041-50. PMID 19515786 DOI: 10.1128/Jvi.00382-09  0.335
Show low-probability matches.